The challenge

A Korean biotech company had strong data and a clear innovation — but no roadmap for turning that into commercial traction in Europe. They had tried to navigate the landscape independently and found it resistant. The relationships they needed weren't accessible through conventional channels, and the window to secure meaningful partnerships was not unlimited.

The approach

DSA mapped the right partnership targets across Europe — not a long list, but the right ones for this specific innovation at this specific stage. We made introductions through our network, prepared the team for each conversation, and stayed present through the negotiation process. The goal was not just access, but outcomes — signed agreements, not just open doors.

The outcome

Within 6 months the company had 2 signed partnership agreements and a pipeline worth €3M+ in potential revenue. DSA didn't advise from the sidelines — they were in the room. That presence made the difference between conversations that stalled and deals that closed.